Huntington’s Disease

Huntington’s Disease

Uncovering markers of disease progression in Huntington’s disease 2:08
Uncovering markers of disease progression in Huntington’s disease
Tiago Mestre • 26 Apr 2021
The latest clinical trials in Huntington’s disease: valbenazine, targeting behavior, and novel DMTs 4:28
The latest clinical trials in Huntington’s disease: valbenazine, targeting behavior, and novel DMTs
Tiago Mestre • 26 Apr 2021
The role of polyglutamine, epigenetics and RNA in Huntington’s disease 2:29
The role of polyglutamine, epigenetics and RNA in Huntington’s disease
Henry Paulson • 9 Sep 2020
The need for biomarkers to begin clinical trials for ataxia treatment 1:27
The need for biomarkers to begin clinical trials for ataxia treatment
Henry Paulson • 9 Sep 2020
Introduction to repeat expansion diseases 2:31
Introduction to repeat expansion diseases
Henry Paulson • 9 Sep 2020
Appraisal of Huntington’s disease clinical trials 2:50
Appraisal of Huntington’s disease clinical trials
Joaquim Ferreira • 4 Sep 2020
The importance of diagnosis for Huntington’s disease phenocopies 3:19
The importance of diagnosis for Huntington’s disease phenocopies
Amanda Krause • 10 Sep 2020
The problems arising in ASO clinical trials and future preparations 3:38
The problems arising in ASO clinical trials and future preparations
Joaquim Ferreira • 4 Sep 2020
Differential diagnosis of Huntington’s disease phenocopies 4:21
Differential diagnosis of Huntington’s disease phenocopies
Amanda Krause • 10 Sep 2020
Endo-lysosomal pathway proteins as potential Huntington’s disease biomarkers 4:52
Endo-lysosomal pathway proteins as potential Huntington’s disease biomarkers
Edward Wild • 4 Sep 2020
ASO tominersen for Huntington’s disease in Phase III trials 2:20
ASO tominersen for Huntington’s disease in Phase III trials
Edward Wild • 4 Sep 2020
Ethical concerns associated with genetic testing 2:01
Ethical concerns associated with genetic testing
Amanda Krause • 10 Sep 2020
Molecular therapeutic development for neurodegenerative disorders 2:42
Molecular therapeutic development for neurodegenerative disorders
Edward Wild • 4 Sep 2020
Gene-environment interactions in Huntington’s disease 3:34
Gene-environment interactions in Huntington’s disease
Anthony Hannan • 20 Jul 2020
Gut microbiota as a potential therapeutic target in Huntington’s disease 2:01
Gut microbiota as a potential therapeutic target in Huntington’s disease
Anthony Hannan • 20 Jul 2020
Gene-environment interactions and neurodegeneration 1:48
Gene-environment interactions and neurodegeneration
Tara Spires-Jones • 16 Jul 2020
The content of VJNeurology is intended for healthcare professionals